Pipeline
Forest small banner

Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.

Therapy
Product
Indication
Cell
Development
Pre-clinical
Phase I
Phase II
Phase III
Market Introduction
Partner

oNKord®

GTA002
AML/MM
NK Cell
Phase II
2024

JP: inno.N;
KR: inno.N

oNKord®
GTA002
AML/MM
NK Cell
II
2024

JP: inno.N;
KR: inno.N

GTA002
Solid Tumors
NK Cell
Pre-clinical
TBA

Glycostem

oNKord®
GTA002
Solid Tumors
NK Cell
PRE
TBA

Glycostem

viveNK™

GTA102
Colorectal cancer
CAR-NK
Pre-clinical
TBA

Glycostem

viveNK™
GTA102
Colorectal cancer
CAR-NK
PRE
TBA

Glycostem

GTA103
Glioblastoma
CAR-NK
Pre-clinical
TBA

inno.N

viveNK™
GTA103
Glioblastoma
CAR-NK
PRE
TBA

inno.N

GTA104
Other Solid Tumors
CAR-NK
Pre-clinical
TBA

inno.N

viveNK™
GTA104
Other Solid Tumors
CAR-NK
PRE
TBA

inno.N

GTA201
N/D
TCR-NK
Development
TBA

Glycostem

viveNK™
GTA201
N/D
TCR-NK
DEV
TBA

Glycostem

Therapy
Phase
Market introduction

oNKord®

GTA002
AML/MM
NK Cell
Phase II
2024

JP: inno.N;
KR: inno.N

oNKord®
GTA002
AML/MM
NK Cell
II
2024

JP: inno.N;
KR: inno.N

GTA002
Solid Tumors
NK Cell
Pre-clinical
TBA

Glycostem

oNKord®
GTA002
Solid Tumors
NK Cell
PRE
TBA

Glycostem

viveNK™

GTA102
Colorectal cancer
CAR-NK
Pre-clinical
TBA

Glycostem

viveNK™
GTA102
Colorectal cancer
CAR-NK
PRE
TBA

Glycostem

GTA103
Glioblastoma
CAR-NK
Pre-clinical
TBA

inno.N

viveNK™
GTA103
Glioblastoma
CAR-NK
PRE
TBA

inno.N

GTA104
Other Solid Tumors
CAR-NK
Pre-clinical
TBA

inno.N

viveNK™
GTA104
Other Solid Tumors
CAR-NK
PRE
TBA

inno.N

GTA201
N/D
TCR-NK
Development
TBA

Glycostem

viveNK™
GTA201
N/D
TCR-NK
DEV
TBA

Glycostem